Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997630970> ?p ?o ?g. }
- W2997630970 endingPage "7141" @default.
- W2997630970 startingPage "7132" @default.
- W2997630970 abstract "// Hideyuki Matsushima 1 , Masaki Kaibori 1 , Masahiko Hatta 1 , Morihiko Ishizaki 1 , Richi Nakatake 1 , Tadayoshi Okumura 1 , 2 , Kengo Yoshii 3 and Tomoki Todo 4 1 Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan 2 Research Organization of Science and Technology, Ritsumeikan University, Kusatsu, Shiga, Japan 3 Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan 4 Division of Innovative Cancer Therapy, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan Correspondence to: Masaki Kaibori, email: kaibori@hirakata.kmu.ac.jp Keywords: oncolytic virus; herpes simplex virus; neuroendocrine tumor; mouse xenograft model Received: August 22, 2019 Accepted: December 02, 2019 Published: December 24, 2019 ABSTRACT BACKGROUND: Few chemotherapies are available for neuroendocrine tumors, especially for highly malignant neuroendocrine cancers. The third-generation oncolytic herpes simplex virus type 1 (HSV-1) T-01 selectively replicates in tumor cells and shows cytotoxicity against tumor cells without damaging surrounding normal tissues. We examined the antitumor effect of T-01 to explore novel treatments for patients with neuroendocrine tumors. METHODS: The cytotoxicity of T-01 was tested in two human and one murine neuroendocrine tumor cell lines in vitro . Mouse models with subcutaneously implanted human neuroendocrine tumor QGP1 cells were used to investigate T-01 efficacy in vivo . RESULTS: T-01 showed cytotoxicity against the three cell lines in vitro . In xenograft models, the growth of tumors derived from QGP1 cells was inhibited by T-01 compared with control group. Although weight loss of mice was observed with tumor growth in the control group, it was suppressed by T-01 administration. The antitumor effects of T-01 were dependent on virus concentration and frequency of administration. CONCLUSIONS: T-01 effectively inhibits tumor cell proliferation in a poorly differentiated NEC mouse model. These results suggest that the third-generation oncolytic HSV-1 may serve as a novel treatment for patients with neuroendocrine tumors." @default.
- W2997630970 created "2020-01-10" @default.
- W2997630970 creator A5039594321 @default.
- W2997630970 creator A5046264170 @default.
- W2997630970 creator A5049184366 @default.
- W2997630970 creator A5053874442 @default.
- W2997630970 creator A5077940502 @default.
- W2997630970 creator A5080949911 @default.
- W2997630970 creator A5084287355 @default.
- W2997630970 creator A5084994130 @default.
- W2997630970 date "2019-12-24" @default.
- W2997630970 modified "2023-10-15" @default.
- W2997630970 title "Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models" @default.
- W2997630970 cites W1209009237 @default.
- W2997630970 cites W1555094309 @default.
- W2997630970 cites W1964561650 @default.
- W2997630970 cites W1970212185 @default.
- W2997630970 cites W1989033119 @default.
- W2997630970 cites W2026234789 @default.
- W2997630970 cites W2026406742 @default.
- W2997630970 cites W2046239281 @default.
- W2997630970 cites W2054924946 @default.
- W2997630970 cites W2057382033 @default.
- W2997630970 cites W2078835828 @default.
- W2997630970 cites W2081457024 @default.
- W2997630970 cites W2086591619 @default.
- W2997630970 cites W2087110939 @default.
- W2997630970 cites W2093053044 @default.
- W2997630970 cites W2121190453 @default.
- W2997630970 cites W2129645310 @default.
- W2997630970 cites W2158058958 @default.
- W2997630970 cites W2161676563 @default.
- W2997630970 cites W2165320653 @default.
- W2997630970 cites W2165434443 @default.
- W2997630970 cites W2165652424 @default.
- W2997630970 cites W2191169743 @default.
- W2997630970 cites W2213024131 @default.
- W2997630970 cites W2315116030 @default.
- W2997630970 cites W2428390281 @default.
- W2997630970 cites W2497822529 @default.
- W2997630970 cites W2745159723 @default.
- W2997630970 cites W2758603625 @default.
- W2997630970 cites W2768561156 @default.
- W2997630970 cites W2776551433 @default.
- W2997630970 cites W2793699285 @default.
- W2997630970 cites W2900773338 @default.
- W2997630970 doi "https://doi.org/10.18632/oncotarget.27391" @default.
- W2997630970 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6935252" @default.
- W2997630970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31903171" @default.
- W2997630970 hasPublicationYear "2019" @default.
- W2997630970 type Work @default.
- W2997630970 sameAs 2997630970 @default.
- W2997630970 citedByCount "12" @default.
- W2997630970 countsByYear W29976309702020 @default.
- W2997630970 countsByYear W29976309702021 @default.
- W2997630970 countsByYear W29976309702022 @default.
- W2997630970 countsByYear W29976309702023 @default.
- W2997630970 crossrefType "journal-article" @default.
- W2997630970 hasAuthorship W2997630970A5039594321 @default.
- W2997630970 hasAuthorship W2997630970A5046264170 @default.
- W2997630970 hasAuthorship W2997630970A5049184366 @default.
- W2997630970 hasAuthorship W2997630970A5053874442 @default.
- W2997630970 hasAuthorship W2997630970A5077940502 @default.
- W2997630970 hasAuthorship W2997630970A5080949911 @default.
- W2997630970 hasAuthorship W2997630970A5084287355 @default.
- W2997630970 hasAuthorship W2997630970A5084994130 @default.
- W2997630970 hasBestOaLocation W29976309701 @default.
- W2997630970 hasConcept C109316439 @default.
- W2997630970 hasConcept C126322002 @default.
- W2997630970 hasConcept C143998085 @default.
- W2997630970 hasConcept C150903083 @default.
- W2997630970 hasConcept C202751555 @default.
- W2997630970 hasConcept C203014093 @default.
- W2997630970 hasConcept C207001950 @default.
- W2997630970 hasConcept C2522874641 @default.
- W2997630970 hasConcept C2779066768 @default.
- W2997630970 hasConcept C2781196997 @default.
- W2997630970 hasConcept C3020616263 @default.
- W2997630970 hasConcept C502942594 @default.
- W2997630970 hasConcept C54355233 @default.
- W2997630970 hasConcept C55493867 @default.
- W2997630970 hasConcept C71924100 @default.
- W2997630970 hasConcept C81885089 @default.
- W2997630970 hasConcept C82210918 @default.
- W2997630970 hasConcept C86803240 @default.
- W2997630970 hasConceptScore W2997630970C109316439 @default.
- W2997630970 hasConceptScore W2997630970C126322002 @default.
- W2997630970 hasConceptScore W2997630970C143998085 @default.
- W2997630970 hasConceptScore W2997630970C150903083 @default.
- W2997630970 hasConceptScore W2997630970C202751555 @default.
- W2997630970 hasConceptScore W2997630970C203014093 @default.
- W2997630970 hasConceptScore W2997630970C207001950 @default.
- W2997630970 hasConceptScore W2997630970C2522874641 @default.
- W2997630970 hasConceptScore W2997630970C2779066768 @default.
- W2997630970 hasConceptScore W2997630970C2781196997 @default.
- W2997630970 hasConceptScore W2997630970C3020616263 @default.
- W2997630970 hasConceptScore W2997630970C502942594 @default.
- W2997630970 hasConceptScore W2997630970C54355233 @default.